GO:0038172 interleukin-33-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038172 describes the molecular signaling cascade triggered when interleukin-33 (IL-33) binds its receptor on the surface of a target cell, culminating in regulation of downstream cellular processes such as transcription.
• IL-33 signaling is a key alarmin pathway that modulates sensory neuronal excitability, immune cell function, and cartilage homeostasis.
• The pathway requires MAP kinase, phosphoinositide 3-kinase (PI3K), and nuclear factor-kB (NF-kB) signaling to inhibit expression of atherosclerosis-related genes in human macrophages.
• IL-33-mediated signaling regulates microRNA expression in human cord blood-derived mast cells, with implications for infection, immunity, and inflammation.
• Dysregulation of IL-33 signaling contributes to knee joint chondrocyte degeneration under mechanical loading, making it a target for osteoarthritis research.
• CRISPR-based knockout, knock-in, and overexpression models are essential for dissecting the causal roles of IL-33 pathway components in disease.
Description
Interleukin-33 (IL-33) is a nuclear cytokine of the IL-1 family that acts as an alarmin when released from damaged or stressed cells. The Gene Ontology term GO:0038172, interleukin-33-mediated signaling pathway, defines the series of molecular signals initiated by IL-33 binding to its receptor on the surface of a target cell and ending with regulation of a downstream cellular process, such as transcription. This pathway is of intense research interest because it bridges innate immunity, neuronal excitability, and tissue remodeling. In sensory neurons, IL-33-mediated inhibition of A-type K+ channels induces hyperexcitability and nociceptive behaviors in mice, directly linking the pathway to pain signaling. In human macrophages, IL-33-mediated inhibition of key atherosclerosis-related genes requires MAP kinase, PI3K, and NF-kB signaling, demonstrating the pathway's broad transcriptional impact. In mast cells, IL-33 regulates microRNA expression with implications for infection and inflammation. In chondrocytes, IL-33 mediates mechanical-loading-induced degeneration of knee joint cartilage, highlighting its role in osteoarthritis. Understanding GO:0038172 is therefore critical for researchers studying inflammation, pain, immunity, and degenerative joint disease.
interleukin-33-mediated signaling pathway At A Glance
| GO ID | GO:0038172 |
|---|---|
| GO term | interleukin-33-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | IL-33-mediated signaling pathway; IL33 signaling pathway; interleukin-33-mediated signalling pathway; interleukin-33 signaling pathway |
| Definition | The series of molecular signals initiated by interleukin-33 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| Major function | Transduces IL-33 alarmin signals from the cell surface to transcriptional and post-transcriptional regulators, modulating immunity, neuronal excitability, and tissue homeostasis. |
| Key receptor | IL-33 binds to its receptor complex on target cells, initiating intracellular signaling cascades. |
| Major signaling mediators | MAP kinase, phosphoinositide 3-kinase (PI3K), and nuclear factor-kB (NF-kB) pathways. |
| Physiological contexts | Sensory neuronal hyperexcitability and nociception; knee joint chondrocyte degeneration; macrophage gene regulation; mast cell microRNA regulation. |
What Is GO:0038172?
GO:0038172, interleukin-33-mediated signaling pathway, is defined as the series of molecular signals initiated by interleukin-33 binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. In simpler terms, it is the entire communication chain that starts when IL-33 docks onto its receptor and finishes with changes inside the cell, such as turning genes on or off. This term is a biological_process in the Gene Ontology and includes synonyms such as IL-33-mediated signaling pathway, IL33 signaling pathway, interleukin-33-mediated signalling pathway, and interleukin-33 signaling pathway.
Why Is interleukin-33-mediated signaling pathway Important in Cell Biology?
GO:0038172 is important because IL-33-mediated signaling is a central alarmin pathway that translates tissue damage or stress into immune, neuronal, and structural responses. It directly controls sensory neuronal excitability and pain behaviors, drives transcriptional programs in macrophages that influence atherosclerosis, regulates microRNA networks in mast cells relevant to infection and immunity, and mediates mechanical-loading-induced cartilage degeneration in the knee joint. Because these processes are implicated in chronic pain, cardiovascular disease, inflammatory disorders, and osteoarthritis, the pathway is a high-value target for both mechanistic studies and therapeutic development.
• Controls sensory neuronal hyperexcitability and nociceptive behaviors via inhibition of A-type K+ channels.
• Regulates key atherosclerosis-related genes in human macrophages through MAP kinase, PI3K, and NF-kB signaling.
• Modulates microRNA expression in human cord blood-derived mast cells, impacting infection, immunity, and inflammation.
• Mediates mechanical-loading-induced degeneration of knee joint chondrocytes, linking the pathway to osteoarthritis.
• Serves as a bridge between innate immune alarmin signaling and transcriptional regulation.
• Provides mechanistic insight into how tissue-derived IL-33 alters pain sensitivity.
• Offers candidate targets for anti-inflammatory and analgesic drug discovery.
• Is relevant to cartilage biology and joint disease progression.
• Enables CRISPR-based functional genomics of IL-33 pathway components.
• Supports biomarker and therapeutic research in immunity and inflammation.
What Happens During interleukin-33-mediated signaling pathway?
IL-33 binding to its receptor on the target cell surface
In simple terms: IL-33 acts like a key that fits into a lock on the outside of a cell.
The pathway begins when interleukin-33 binds to its receptor on the surface of a target cell, as defined by GO:0038172. This receptor engagement is the initiating event that converts an extracellular alarmin signal into intracellular signaling. In sensory neurons, this binding leads to downstream modulation of ion channels and neuronal excitability. In human macrophages, receptor activation triggers intracellular cascades that ultimately regulate gene expression.
Activation of MAP kinase, PI3K, and NF-kB signaling
In simple terms: Once the lock is turned, several internal messenger chains start working.
Following receptor engagement, IL-33-mediated signaling requires MAP kinase, phosphoinositide 3-kinase (PI3K), and nuclear factor-kB (NF-kB) signaling pathways. Buckley et al. demonstrated that the IL-33-mediated inhibition of expression of two key genes implicated in atherosclerosis in human macrophages depends on these three signaling arms. This indicates that the pathway converges on multiple intracellular kinases and transcription factors to regulate downstream cellular processes.
Regulation of downstream transcription and gene expression
In simple terms: The signal reaches the nucleus and changes which genes are turned on or off.
The terminal step of GO:0038172 is regulation of a downstream cellular process, e.g. transcription. In human macrophages, IL-33 signaling inhibits the expression of key atherosclerosis-related genes, an effect that requires MAP kinase, PI3K, and NF-kB pathways. This transcriptional regulation is a core output of the pathway and explains its broad impact on cell behavior.
Modulation of microRNA networks in mast cells
In simple terms: The signal can also change small regulatory RNA molecules inside the cell.
IL-33-mediated signaling regulates microRNAs in human cord blood-derived mast cells, with implications for infection, immunity, and inflammation. This demonstrates that the pathway can act post-transcriptionally through microRNA regulation, extending its influence beyond direct transcriptional control.
Effects on ion channels and neuronal excitability
In simple terms: In nerve cells, the signal can make them more excitable and cause pain.
IL-33-mediated inhibition of A-type K+ channels induces sensory neuronal hyperexcitability and nociceptive behaviors in mice. This shows that GO:0038172 can regulate downstream cellular processes beyond transcription, including ion channel function and neuronal firing, directly linking the pathway to pain signaling.
Role in chondrocyte degeneration under mechanical loading
In simple terms: In joint cartilage cells, the signal can contribute to wear and tear.
IL-33 mediates mechanical-loading-induced degeneration of knee joint chondrocytes. This indicates that the pathway operates in cartilage tissue and contributes to cellular changes that underlie joint degeneration, expanding the physiological relevance of GO:0038172 to musculoskeletal biology.
Key Genes Involved in GO:0038172 interleukin-33-mediated signaling pathway
The following genes and proteins are central to the interleukin-33-mediated signaling pathway (GO:0038172) based on published functional studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL33 | Ligand that initiates the pathway by binding its receptor | Alarmin cytokine; target for pain, inflammation, and cartilage studies |
| IL1RL1 (ST2) | Receptor for IL-33 on target cells | Mediates pathway initiation; key for signaling assays |
| MAPK1/3 | MAP kinase signaling downstream of IL-33 | Required for IL-33-mediated gene inhibition in macrophages |
| PIK3CA/PIK3CB | Phosphoinositide 3-kinase signaling | Required for IL-33-mediated gene inhibition in macrophages |
| NFKB1 | Nuclear factor-kB transcription factor | Required for IL-33-mediated gene regulation |
| KCNA4 | A-type K+ channel subunit | IL-33-mediated inhibition induces neuronal hyperexcitability |
| KCND2 | A-type K+ channel subunit | Contributes to sensory neuronal excitability changes |
| MIR21 | MicroRNA regulated by IL-33 in mast cells | Implicated in infection, immunity, and inflammation |
| MIR146A | MicroRNA regulated by IL-33 in mast cells | Implicated in inflammatory regulation |
| MMP13 | Matrix metalloproteinase in chondrocytes | Associated with cartilage degeneration under mechanical load |
| ADAMTS5 | Aggrecanase in cartilage | Potential effector of chondrocyte degeneration |
| COL2A1 | Type II collagen in cartilage | Marker of chondrocyte phenotype and degeneration |
| ACAN | Aggrecan core protein in cartilage | Marker of cartilage matrix integrity |
| IL6 | Inflammatory cytokine | Downstream inflammatory mediator in IL-33 signaling contexts |
| TNF | Inflammatory cytokine | Associated with inflammatory responses in pathway studies |
| CXCL8 | Chemokine | Inflammatory mediator potentially regulated by IL-33 signaling |
| SOCS3 | Suppressor of cytokine signaling | Potential negative regulator of IL-33 signaling |
How Is interleukin-33-mediated signaling pathway Regulated?
IL-33-mediated signaling is regulated at multiple levels. The pathway requires MAP kinase, phosphoinositide 3-kinase (PI3K), and nuclear factor-kB (NF-kB) signaling for its inhibitory effects on gene expression in human macrophages. In sensory neurons, IL-33-mediated inhibition of A-type K+ channels is a regulatory mechanism that controls neuronal excitability and nociceptive behaviors. In mast cells, IL-33 regulates microRNA expression, adding a post-transcriptional layer of control. In chondrocytes, mechanical loading regulates IL-33-mediated degeneration, indicating that biomechanical cues modulate pathway activity.
interleukin-33-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL33 | Pain and sensory neuronal hyperexcitability | Knockout mouse or sensory neuron-specific KO |
| IL1RL1 (ST2) | Atherosclerosis and macrophage gene regulation | Human macrophage KO or knockdown |
| KCNA4 | Sensory neuronal excitability and nociception | Point-mutation or overexpression in neurons |
| MMP13 | Osteoarthritis and cartilage degeneration | Chondrocyte KO or knock-in under mechanical loading |
| MIR21 | Infection, immunity, and inflammation | Mast cell overexpression or knockout |
IL-33 signaling in pain and sensory neuronal disorders
IL-33-mediated inhibition of A-type K+ channels induces sensory neuronal hyperexcitability and nociceptive behaviors in mice. This directly implicates GO:0038172 in pain processing and suggests that targeting the pathway could reduce neuronal hyperexcitability in chronic pain conditions.
IL-33 signaling in atherosclerosis and cardiovascular disease
In human macrophages, IL-33-mediated inhibition of expression of two key genes implicated in atherosclerosis requires MAP kinase, PI3K, and NF-kB signaling pathways. This links the pathway to atherosclerotic plaque biology and cardiovascular risk.
IL-33 signaling in osteoarthritis and cartilage degeneration
IL-33 mediates mechanical-loading-induced degeneration of knee joint chondrocytes. This positions GO:0038172 as a contributor to osteoarthritis pathogenesis and a potential target for cartilage-protective strategies.
IL-33 signaling in infection, immunity, and inflammation
IL-33-mediated regulation of microRNAs in human cord blood-derived mast cells has implications for infection, immunity, and inflammation. This broadens the disease relevance of the pathway to host defense and inflammatory disorders.
From interleukin-33-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL-33 initiate signaling in target cells? | IL33 knockout or IL1RL1 (ST2) knockout cells |
| Which residues in IL-33 receptor are required for signaling? | Point-mutation knock-in of IL1RL1 |
| How does IL-33 regulate gene expression? | Knock-in of tagged NF-kB or MAPK reporters |
| What is the effect of IL-33 overexpression? | IL33 overexpression in macrophages or chondrocytes |
| How does IL-33 affect microRNA networks? | Mast cell knockout or overexpression followed by microRNA profiling |
| Does IL-33 mediate mechanical-loading degeneration? | Chondrocyte knockout under mechanical loading |
How to Study the interleukin-33-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes | Identify genes regulated by IL-33 signaling |
| Small RNA-seq | MicroRNA expression | Profile IL-33-regulated microRNAs in mast cells |
| Patch-clamp electrophysiology | Ion channel currents and excitability | Measure A-type K+ channel inhibition by IL-33 |
| Western blot | Protein phosphorylation and expression | Detect MAPK, PI3K, and NF-kB activation |
| CRISPR knockout screening | Gene essentiality for pathway output | Discover novel regulators of IL-33 signaling |
| Luciferase reporter assay | Transcriptional activity | Measure NF-kB or other promoter activity |
| Mechanical loading bioreactor | Chondrocyte degeneration markers | Study IL-33 in osteoarthritis models |
| ELISA | Cytokine and chemokine secretion | Quantify inflammatory mediators |
Transcriptomic profiling of IL-33-stimulated cells
RNA-seq can be used to measure transcriptional changes downstream of IL-33-mediated signaling. In human macrophages, IL-33 inhibits expression of atherosclerosis-related genes, and RNA-seq would identify the full set of regulated transcripts. In chondrocytes, RNA-seq under mechanical loading can reveal degeneration-associated gene programs.
MicroRNA profiling in mast cells
Small RNA sequencing or microRNA arrays can quantify IL-33-mediated regulation of microRNAs in human cord blood-derived mast cells, as demonstrated by Bakhashab et al.. This approach identifies post-transcriptional effectors of the pathway.
Electrophysiology for neuronal excitability
Patch-clamp electrophysiology measures A-type K+ channel currents and neuronal excitability following IL-33 exposure. Wang et al. used this approach to show that IL-33-mediated inhibition of A-type K+ channels induces sensory neuronal hyperexcitability.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes required for IL-33-mediated signaling outputs, such as MAP kinase, PI3K, and NF-kB components. This unbiased approach can uncover novel regulators of GO:0038172.
How CRISPR Can Be Used to Study GO:0038172 interleukin-33-mediated signaling pathway
Knockout
CRISPR knockout of IL33, IL1RL1 (ST2), MAPK1/3, PIK3CA, or NFKB1 can abolish IL-33-mediated signaling and reveal which components are essential for downstream transcriptional or neuronal outputs. Knockout of KCNA4 or KCND2 can test their role in IL-33-mediated neuronal hyperexcitability.
Point Mutation
Point-mutation knock-in can be used to dissect specific phosphorylation sites or receptor residues required for IL-33-mediated signaling. For example, mutating key residues in IL1RL1 or downstream kinases can test their necessity for pathway activation.
Knock-in
Knock-in of tagged IL33, IL1RL1, or NF-kB subunits enables imaging and biochemical tracking of the pathway in live cells. Tagged knock-in models can also be used to monitor pathway activation in specific tissues such as sensory neurons or chondrocytes.
Overexpression
Overexpression of IL33 or constitutively active downstream components can amplify pathway signaling and reveal gain-of-function phenotypes, such as enhanced microRNA regulation in mast cells or increased chondrocyte degeneration.
How EDITGENE Supports interleukin-33-mediated signaling pathway Research
Researchers studying interleukin-33-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway initiation, signal transduction, or downstream transcriptional regulation. EDITGENE provides CRISPR-based cell model services that enable precise genetic manipulation of IL33, IL1RL1, MAPK, PI3K, NF-kB, and other pathway components.
Contact EDITGENE today to design your custom CRISPR model for interleukin-33-mediated signaling pathway research.
Frequently Asked Questions About interleukin-33-mediated signaling pathway
What is GO:0038172?
GO:0038172 is the Gene Ontology term for interleukin-33-mediated signaling pathway, defined as the series of molecular signals initiated by interleukin-33 binding to its receptor on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription.
What is the interleukin-33-mediated signaling pathway?
It is the signaling cascade triggered when IL-33 binds its receptor on a target cell, leading to intracellular events such as MAP kinase, PI3K, and NF-kB activation and changes in gene expression.
What genes are involved in interleukin-33-mediated signaling pathway?
Key genes include IL33, IL1RL1 (ST2), MAPK1/3, PIK3CA, NFKB1, KCNA4, KCND2, and microRNAs such as MIR21 and MIR146A.
How does IL-33 signaling cause pain?
IL-33-mediated inhibition of A-type K+ channels induces sensory neuronal hyperexcitability and nociceptive behaviors in mice.
What is the role of IL-33 in atherosclerosis?
IL-33-mediated inhibition of expression of two key genes implicated in atherosclerosis in human macrophages requires MAP kinase, PI3K, and NF-kB signaling pathways.
How does IL-33 affect mast cells?
IL-33 regulates microRNAs in human cord blood-derived mast cells, with implications for infection, immunity, and inflammation.
Is IL-33 involved in osteoarthritis?
Yes, IL-33 mediates mechanical-loading-induced degeneration of knee joint chondrocytes.
What signaling pathways are required for IL-33-mediated gene regulation?
MAP kinase, phosphoinositide 3-kinase (PI3K), and nuclear factor-kB (NF-kB) signaling pathways are required.
How can I study IL-33 signaling with CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models can be used to test the causal role of IL33, IL1RL1, MAPK, PI3K, and NF-kB components.
What are the synonyms for GO:0038172?
Synonyms include IL-33-mediated signaling pathway, IL33 signaling pathway, interleukin-33-mediated signalling pathway, and interleukin-33 signaling pathway.
Conclusion
GO:0038172, interleukin-33-mediated signaling pathway, is a biologically_process that captures the full cascade from IL-33 receptor binding to downstream cellular regulation. Its importance spans sensory neuronal excitability and pain, macrophage gene regulation in atherosclerosis, microRNA control in mast cells, and chondrocyte degeneration in osteoarthritis. Researchers can leverage CRISPR-based knockout, point-mutation, knock-in, and overexpression models to dissect the causal roles of IL33, IL1RL1, MAPK, PI3K, NF-kB, and other pathway components. EDITGENE provides end-to-end services to accelerate this research.
References
- 1. Wang Y et al.. 2022. Interleukin 33-mediated inhibition of A-type K(+) channels induces sensory neuronal hyperexcitability and nociceptive behaviors in mice.. Theranostics 12(5):2232-2247 PMID: 35265208
- 2. Zhang J et al.. 2025. Interleukin-33-Mediated Mechanical-Loading Induced Degeneration of Knee Joint Chondrocytes.. FASEB Bioadv 7(12):e70072 PMID: 41383711
- 3. Buckley ML et al.. 2019. The interleukin-33-mediated inhibition of expression of two key genes implicated in atherosclerosis in human macrophages requires MAP kinase, phosphoinositide 3-kinase and nuclear factor-κB signaling pathways.. Sci Rep 9(1):11317 PMID: 31383884
- 4. Bakhashab S et al.. 2024. Interleukin-33 mediated regulation of microRNAs in human cord blood-derived mast cells: Implications for infection, immunity, and inflammation.. PLoS One 19(11):e0314446 PMID: 39591475
